A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Orphenadrine

Muscle Relaxant class · 7 generic manufacturers · 8 ANDAs filed at FDA.

First FDA approval1998-06-19
Generic availableYes · 7 mfrs
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one

$3.5M in CY2024 Part D spend108K claims · 67K beneficiaries · 329 plans surveyed

Lowest NADAC
$0.458/unit
6 NDCs benchmarked, lowest of all strengths.
Average NADAC
$3.33
Across all dosage forms in distribution.
Highest NADAC
$7.07
Wide spread — brand-strength NDCs still in market.
Plans with PA
25 / 329
Limited PA friction.

Questions a plan sponsor actually asks.

FAQPage schema10 entries indexed · 4 visible
What is Orphenadrine used for?

Orphenadrine is a Muscle Relaxant medication tracked in Medicare Part D.

Is there a generic for Orphenadrine?

Yes. 8 ANDAs filed at FDA, 7 generic manufacturers currently shipping.

How much does my plan pay for Orphenadrine?

Across 329 Part D plans, Orphenadrine averages $3.33/unit (NADAC). Lowest available: $0.458/unit. Highest in distribution: $7.07/unit.

Is Orphenadrine on the FDA shortage list?

No. Orphenadrine is not currently on the FDA Drug Shortage Database.

6 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Same class. Different math.

Muscle Relaxant5 alternatives in D1
01
Carisoprodol
Brand: Soma
$0.067Lowest NADAC
13Generic mfrs
$8.4MCY24 Part D spend
Compare →
02
Chlorzoxazone
Muscle Relaxant
$0.215Lowest NADAC
11Generic mfrs
$24.2MCY24 Part D spend
Compare →
03
Metaxalone
Muscle Relaxant
$0.377Lowest NADAC
6Generic mfrs
$12.6MCY24 Part D spend
Compare →
04
Methocarbamol
Brand: ATMEKSI
$0.037Lowest NADAC
18Generic mfrs
$65.6MCY24 Part D spend
Compare →
05
Methocarbamol Tablets
Brand: Methocarbamol
$0.037Lowest NADAC
0Generic mfrs
CY24 Part D spend
Compare →

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (8 approvals on file) · NADAC unit costs: CMS NADAC weekly file (6 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.